Myogenic Differentiation of iPS Cells Shows Different Efficiency in Simultaneous Comparison of Protocols

Cells. 2021 Jul 2;10(7):1671. doi: 10.3390/cells10071671.

Abstract

Induced pluripotent stem (iPS) cells constitute a perfect tool to study human embryo development processes such as myogenesis, thanks to their ability to differentiate into three germ layers. Currently, many protocols to obtain myogenic cells have been described in the literature. They differ in many aspects, such as media components, including signaling modulators, feeder layer constituents, and duration of culture. In our study, we compared three different myogenic differentiation protocols to verify, side by side, their efficiency. Protocol I was based on embryonic bodies differentiation induction, ITS addition, and selection with adhesion to collagen I type. Protocol II was based on strong myogenic induction at the embryonic bodies step with BIO, forskolin, and bFGF, whereas cells in Protocol III were cultured in monolayers in three special media, leading to WNT activation and TGF-β and BMP signaling inhibition. Myogenic induction was confirmed by the hierarchical expression of myogenic regulatory factors MYF5, MYOD, MYF6 and MYOG, as well as the expression of myotubes markers MYH3 and MYH2, in each protocol. Our results revealed that Protocol III is the most efficient in obtaining myogenic cells. Furthermore, our results indicated that CD56 is not a specific marker for the evaluation of myogenic differentiation.

Keywords: CD56; differentiation; induced pluripotent stem cells (iPS); myogenesis; myogenic factors; skeletal muscle.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism
  • Cell Culture Techniques*
  • Cell Differentiation / drug effects
  • Colforsin / pharmacology
  • Collagen Type I / pharmacology
  • Culture Media / pharmacology*
  • Cytoskeletal Proteins / genetics
  • Cytoskeletal Proteins / metabolism
  • Embryoid Bodies / cytology
  • Embryoid Bodies / drug effects*
  • Embryoid Bodies / metabolism
  • Fibroblast Growth Factor 2 / pharmacology
  • Fibroblasts / cytology
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Gene Expression
  • Humans
  • Indoles / pharmacology
  • Induced Pluripotent Stem Cells / cytology
  • Induced Pluripotent Stem Cells / drug effects*
  • Induced Pluripotent Stem Cells / metabolism
  • Insulin / pharmacology
  • Muscle Development / drug effects*
  • Muscle Development / genetics
  • Muscle Fibers, Skeletal / cytology
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism
  • MyoD Protein / genetics
  • MyoD Protein / metabolism
  • Myogenic Regulatory Factor 5 / genetics
  • Myogenic Regulatory Factor 5 / metabolism
  • Myogenic Regulatory Factors / genetics
  • Myogenic Regulatory Factors / metabolism
  • Myogenin / genetics
  • Myogenin / metabolism
  • Oximes / pharmacology
  • Selenium / pharmacology
  • Transferrin / pharmacology

Substances

  • 6-bromoindirubin-3'-oxime
  • Biomarkers
  • Collagen Type I
  • Culture Media
  • Cytoskeletal Proteins
  • Indoles
  • Insulin
  • MYF5 protein, human
  • MYH3 polypeptide, human
  • MYOG protein, human
  • MyoD Protein
  • MyoD1 myogenic differentiation protein
  • Myogenic Regulatory Factor 5
  • Myogenic Regulatory Factors
  • Myogenin
  • Oximes
  • Transferrin
  • myogenic factor 6
  • Fibroblast Growth Factor 2
  • Colforsin
  • Selenium